The skeleton is the most frequently affected organ in metastatic breast cancer \[[@CR1]\]. Up to 2.6 % of all breast cancer patients have bone metastases at the initial diagnosis and up to 15 % will develop bone metastases within 15 years \[[@CR2], [@CR3]\].

Drug-resistant pain, pathological fractures, and neurological complications are the most common consequences, inducing significant morbidity and impairment of quality of life. The treatment of bone metastases requires a multidisciplinary approach with surgical, pain therapeutical, oncological, and radiotherapeutical care.

Indications for radiotherapy (RT) are pain, existing or impending instability, neurological symptoms due to compression of the spinal cord, or previous surgical intervention \[[@CR4]\]. RT offers pain relief in 50--80 % of patients. The benefit of RT concerning pain and recalcification of osteolytic metastases may be greater when the therapy is combined with concomitant administration of bisphosphonates \[[@CR1]\].

Orthopedic thoracic corsets are used to prevent vertebral fractures and consecutive spinal cord compression. Immobilization for pain and suspected instability areconsequences of spinal metastases. The use of a validated scoring system to assess the stability of spinal bone metastases may prevent physicians from overdiagnosis of instability and, thus, improve the quality of life in palliative-stage patients.

The aim of this retrospective analysis of breast cancer patients with bone metastases was to systematically assess the bone lesions in terms of stability, fractures prior to and following RT, survival, and predictive factors for stability.

Patients and methods {#Sec1}
====================

This analysis was based on 115 patients, whose 157 osseous lesions were treated by RT for metastases of the vertebral column due to histologically diagnosed breast carcinoma from January 2000 to January 2012. Patients underwent regular follow-up examinations including computer tomography (CT) imaging.

Patients with osteolytic metastases, localization in the thoracic and lumbar spine, and a minimum duration of follow-up treatment of 6 months were included in this retrospective analysis. Patient data were taken from a cancer registry. Patients who were irradiated in several regions were regarded separately for each region in our analysis. Within each region, the most severe metastasis according to the Taneichi score was included in the analysis \[[@CR6]\]. Accordingly, 115 patients with 157 irradiated regions, including 480 vertebral bodies in the thoracic and lumbar spine, were evaluated. For each region one metastasis with the highest probability of collapse according to the Taneichi score was chosen for the examination.

All patients were female. The most frequent histological type was invasive ductal carcinoma (79 %). The Karnofsky Performance Status Scale (KPS) was used to assess performance status \[[@CR5]\]. The diagnosis of bone metastasis was made on the basis of the CT or magnetic resonance imaging (MRI) findings or bone scintigraphy investigations. The patient characteristics are summarized in Table 1.

Table 1Patient characteristics*n*%Age at radiotherapy (years)Median (range)60 (32--88) yearsKarnofsky scale30--60261770--801026590--1002918HistologyInflammatory11Invasive ductal12479Invasive lobular3120Invasive papillary11SiteThoracic11674Lumbar4126Distant metastasesBrain149Lung2617Liver2818Others2215Immunohistochemistry positivityEstrogen receptor13183Progesterone receptor12479Her2-neu4327

The stability of each affected vertebral body was assessed according to the Taneichi score on the basis of the CT image recorded before RT to plan treatment and also in the follow-up stage 3 and 6 months after radiotherapy \[[@CR6]\].

The osteolytic metastases were rated on a scale from A to G. Subtypes A to C were defined as stable, subtypes D to G as unstable (Fig. 1).

Fig. 1Applied score for osteolytic metastases of the thoracic and lumbar spine \[[@CR6]\]

Most patients received additional chemotherapy, endocrine therapy, or bisphosphonates before and after RT. After RT, 91 % of the lesions were treated with bisphosphonates (Table 2), and 61 % of the patients were equipped with an orthopedic thoracic corset.

Table 2Therapy characteristicsRadiotherapy (RT)*n*%10 × 3 Gy895714 × 2.5 Gy251620 × 2 Gy3825Others32Irradiated vertebrae370454--64529\> 64227Concomitant therapyPrior to RTChemotherapy5535Endocrine therapy5837Bisphosphonates5938After RTChemotherapy8152Endocrine therapy10969Bisphosphonates14391StabilityStable prior to RT7246Stable 3 months after RT9762Stable 6 months after RT10768

This study was approved by the institutional ethics committee on 22 October 2012 (nr. S-513/2012).

Radiotherapy {#Sec2}
------------

RT was applied for instability in 67 and 52 % of patients due to pain, when regarding the documented indication for therapy. The treatment was carried out at the department of radiation oncology. RT was planned using virtual simulation based on CT scans, and was performed over a dorsal photon field with energy of 6 MV. The planning target volume (PTV) covered the vertebral body affected as well as bodies immediately above and below. The most frequent radiation schedule was 10 fractions of 3 Gy in 57 % of cases (Table 2). The fractionation schedule was selected individually for each patient, depending on the patient's general state of health, the current staging, response to current therapy, and the respective prognosis.

Statistical analysis {#Sec3}
--------------------

The empirical distribution of continuous variables is described by the number of observations, mean and standard deviation; the description of categorical variables includes the number and percentage of patients belonging to the relevant categories.

The univariate chi-square test was used to evaluate the prognostic factors for the endpoint stabilization of spinal metastases for the factors age, KPS, histology, number of metastasis (1 vs. \> 1), irradiated area (thoracic vs. lumbar spine), hormone receptor status (positive vs. negative), overall dose, and concomitant therapy (chemotherapy, hormone drug therapy, bisphosphonates) separately for the period within 6 months before and after RT.

Survival times are presented graphically, using the Kaplan--Meier method. Patients who were lost to follow-up were included in the statistics as censored observations.

"Bone survival" was defined as the time from the first diagnosed spinal metastases to death. Overall survival was defined as the time from the initial diagnosis of breast cancer to death.

For the distribution of Taneichi score subtypes before and 6 months after RT, the Bowker test was used. Kappa statistics were calculated to detect possible asymmetry in the distribution of the Taneichi score over time.

Overall survival and bone survival were calculated for subgroups divided by the number of irradiated metastases, to account for the acceptance that patients with one metastasis requiring treatment will have a better prognosis than those with multiple metastases.

Results {#Sec4}
=======

The median follow-up of all patients was 16.7 months (mean 19.9, range 0.4--74.7 months). Thirty patients (19 %) died during follow-up. Seventy patients (61 %) had only bone metastases, 45 patients (39 %) had metastases in other distant organs such as t5he liver (*n* = 22), lung (*n* = 19), and brain (*n* = 11).

Before RT, 46 % (*n* = 72) of the lesions were classified as stable according to the Taneichi score. Of the stable bone metastases, none were rated unstable in the further course of study (*p* \< 0.001, McNemar test).

Of the 85 patients (54 %) in whom the metastases were classified as unstable prior to RT, 24 patients were classified as stable after 3 months, and 35 patients stable after 6 months. This means that in total, 61 and 68 % of the bone metastases were stable after 3 and 6 months, respectively (Table 3).

Table 3Results of prognostic factors related to stability*n*%StabilityPrior to RT72543 months after RT96616 months after RT10768General*p* valueAge0.27KPS0.47Histology0.90Number of metastases (1 vs. \> 1)0.27Area (thoracic vs. lumbar spine)0.97Hormone receptor (positive vs. negative)0.18TherapyOverall dose0.12Therapy within 1 year before RTChemotherapy (yes vs. no)0.90Hormone therapy (yes vs. no)0.12Bisphosphonates (yes vs. no)0.62Therapy after RTChemotherapy (yes vs. no)0.21Hormone therapy (yes vs. no)0.88Bisphosphonates (yes vs. no)0.36

The evaluation of the distribution of subtypes A to G showed a major change in the direction of improvement over the course of time. Improvement in the score occurred in 61 % patients (*n* = 95). Improvement of stability was detected in 22 % (*n* = 35) of all cases. This corresponds to an improvement of stability in 45 % of all unstable lesions (*n* = 85). Deterioration of stability was detected in 2 % of cases (*n* = 3). The Bowker test shows the distribution pattern of the subtypes according to the Taneichi score prior to and 6 months after RT. Asymmetry was apparent (*p* = 0.0001) and the correlation (weighted kappa = 0.67) was good (Table 4).

Table 4Distribution of subtypes A to G over the course of time (0--6 months)Bowker test6 months after RTPrior to RTABCDEFGA25101000B111700000C4290200D52412000E82022000F102302100G2000010

Before RT, 30 patients had pathological fractures within the irradiated region. During the follow-up, in seven cases (4.5 %) new fractures were found, of which all but one had been evaluated as unstable before RT (*n* = 6).

Using fractionation patterns with overall doses of 30--40 Gy, there was no correlation between overall dose and stability after RT (*p* = 0.12).

Furthermore, there was no significant correlation in the univariate analysis between stability after RT and the potential predictive factors such as bisphosphonates, chemotherapy, and hormone therapy before and after RT. Further factors tested in the univariate analysis were age, KPS, hormone receptor status, histology, and location of the examined metastasis (lumbar spine vs. thoracic spine; Table 3).

Overall survival was 83 % at 5 years for all patients (Fig. 2). The 5-year survival rate for patients with one treated metastasis and more than one metastasis was 88 and 79 %, respectively. Bone survival for all patients was 69 % (Fig. 3), and 74 and 59 % for patients with one and more than one treated metastasis, respectively.

Fig. 2Overall survival

Fig. 3Bone survival

The difference between the subgroups of patients with one and more than one metastasis in both measured periods, overall survival and bone survival, was not significant, with a p value of 0.12 and 0.078, respectively, in the log-rank test.

Discussion {#Sec5}
==========

Besides pain, the reduced stability is the most frequent reason for radiation of bone metastases. The scoring system by Taneichi et al. classifies osteolytic metastases of the thoracic and lumbar spine by risk factors such as tumor size and involvement of costovertebral joints for the thoracic region (Th 1 to 10) and by tumor size and destruction of the pedicles for the lumbar region (Th11, Th12, and all lumbar vertebrae). Posterior elements seem to have a major impact on stabilization, which was found in biometrical models of the thoracic and lumbar spine vertebrae \[[@CR7]--[@CR9]\].

Before RT, 46 % of the lesions (*n* = 72) were classified as stable, and after 6 months 70 % (*n* = 110) were stable. Patients benefit from stabilized metastases in daily life, as soon as they can omit their corset.

In patients who were treated before the validated score was introduced in the facility in 2011, stability of osteolytic bone lesions was estimated on the basis of several factors such as involvement of the rear edge at the vertebral foramen and pain. According to the documentation, 67 % of the irradiated metastases were unstable. Applying the validated score retrospectively, 54 % of the metastases were rated unstable. The difference is result of the changed criteria.

Fractures were detected in 30 lesions. The follow-up examinations revealed seven patients with progressive bone destruction or new fracture.

According to the literature, symptomatic spinal cord compression in patients with bone metastases can be expectedin 10 % of all cases \[[@CR4]\]. The patients included in our analyses showed less frequent and less severe neurologic deficits. The reasons might be a preference of surgical treatment for certain patients' metastatic spinal cord compression and the poor prognosis of patients with inoperable compression, leading to their disqualification for this analysis due to a lack of follow-up examinations. In our analy­sis three patients had existing symptomatic spinal cord compression. A further four patients revealed less severe deficits, such as incomplete paralyses or disorders in the function of the bowl or bladder due to metastases in the further course of the disease and more than 6 months after RT. Complete paraplegia developed in one pa­tient several years after RT.

The rarity of neurological signs might be caused by the preference of surgery in these patients, as it offers immediate decompression of the spinal cord and stabilization \[[@CR10]\]. In the analyzed cases, RT was preferably applied to prevent neurologic symptoms and pain caused by collapsing metastases.

All examined factors such as age, KPS, hormone receptor status, histology of the primary tumor, and location of the examined metastasis failed to show significant influence on the probability for restabilization after RT. The concomitant therapy with hormone therapy, chemotherapy, and bisphosphonates therapy also did not show any favorable influence in our analysis. Similar results were already observed in an analysis of bone metastases in lung cancer patients \[[@CR11]\].

The predominately used dose schedules for the analyzed cases were 10 fractions of 3 Gy, 14 fractions of2.5 Gy, and 20 fractions of 2 Gy. As suggested by current guidelines, the fractionation schemes were individually selected regarding multiple factors such as prognosis and general state \[[@CR11]\]. One can assume that prolonged radiation has a longer lasting effect on bone metastases and a minor probability of in-field recurrences. Considering the available data from the literature, there seem to be few distinctions between the applied fractionations \[[@CR1], [@CR4]\]. The analysis consistently showed no significant difference in the fractionation schedules used in our study.

Remarkably, this analysis focused on stabilization of irradiated metastasis within 6 months. This implies that there might be limitations, when examining the influence of systemic or long-term therapies.

Improvements in the therapy of bone metastases were accomplished by concomitant drug therapy such as bisphosphonates \[[@CR12]\]. Several trials showed that concomitant bisphosphonates therapy seems to be secure and is assumed to support recalcification. Nevertheless, there is no evidence from controlled prospective trials of the superiority of a combined therapy compared with RT alone \[[@CR1]\]. One recent similar analysis, examining predictive factors for survival of de novo bone-metastasized breast cancer patients, suggests that bisphosphonate treatment might be linked to longer overall survival. According to this report, patients receiving hormone therapy or chemotherapy had no significant survival benefit \[[@CR13]\]. Further reports did not find a benefit when comparing the hormone receptor status with the probability for skeletal complications \[[@CR14]\]. In our analysis we could not detect a benefit for hormone or chemotherapy after RT concerning the endpoint stabilization.

The median overall survival for metastatic breast cancer is long (several years) when compared with other tumors such as lung cancer \[[@CR15]--[@CR17]\]. In our analysis, we measured a survival of 82 % after 5 years, which is longer than the overall survival measured in similar studies \[[@CR10]\]. The extended survival might be a manifestation of the selection criteria, by only including patients with at least 6 months of follow-up. This is also illustrated by the high initial KPS with median value of 80.

Prolonged survival is associated with absent extraskeletal metastases, which was the case in most patients. Sung et al. reported a median survival after the diagnosis of bone-only metastases of 75 months \[95 % confidence interval (CI), 38.6--71.9\] with increased survival of de novo bone metastases \[[@CR13]\]. The number of patients with de novo and bone-only metastases in our analyses was high at 45 %. The comparatively high estimated survival rates emphasize the need for a palliative therapy that is not restricted to pain relief but preserves the patient's physical autonomy.

Conclusion {#Sec6}
==========

The use of a systematic radiological scoring system to classify osteolytic metastases of the vertebral column was shown to be practicable for patients with metastasized breast cancer in the follow-up period after RT, and should be applied in daily routine. The majority of patients showed an improved or unchanged stability of their involved vertebral bodies after 6 months.
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